Abstract: A chemotherapeutic drug composition, prepared by combination of Everolimus, one of the drugs used in the treatment of the metastatic renal cell carcinoma (RCC) comprising 2-3% of the malignant tumors, with the anti-apoptotic Bcl-2 inhibitor ABT-737 for the treatment of RCC tumors that developed drug resistance. The effect of Everolimus and ABT-737 drug composition on cell survival and cell death in Everolimus-resistant RCC cell lines overexpressing Bcl-2 protein was shown by in vitro and in vivo experiments and the mechanism of the effect of the drug composition on RCC has been examined from a molecular point of view. Navitoclax (ABT-263), an orally available analog of ABT-737, and other Bcl-2 inhibitors alone or in combination with Everolimus, which is administered once a day at a dose of 10 mg, for the use in the treatment of Everolimus-resistant RCC.

Abstract: A chemotherapeutic drug composition, prepared by combination of Everolimus, one of the drugs used in the treatment of the metastatic renal cell carcinoma (RCC) comprising 2-3% of the malignant tumors, with the anti-apoptotic Bcl-2 inhibitor ABT-737 for the treatment of RCC tumors that developed drug resistance. The effect of Everolimus and ABT-737 drug composition on cell survival and cell death in Everolimus-resistant RCC cell lines overexpressing Bcl-2 protein was shown by in vitro and in vivo experiments and the mechanism of the effect of the drug composition on RCC has been examined from a molecular point of view. Navitoclax (ABT-263), an orally available analog of ABT-737, and other Bcl-2 inhibitors alone or in combination with Everolimus, which is administered once a day at a dose of 10 mg, for the use in the treatment of Everolimus-resistant RCC.